Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2026)

Takeda Pharmaceutical has reported Non-Current Debt for 9 years, with the latest figure at $27.9 billion in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 7.18% year-over-year to $27.9 billion in Q1 2026; TTM through Mar 2026 was $27.9 billion, a 7.18% increase from a year earlier, with the FY2026 full-year figure at $27.9 billion, up 7.01% from the prior year.
• Non-Current Debt was $27.9 billion for Q1 2026 at Takeda Pharmaceutical, up from $26.0 billion in the prior quarter.
• The five-year high for Non-Current Debt was $35.6 billion in Q1 2022, with the low at $26.0 billion in Q1 2025.
• Average Non-Current Debt over 5 years is $30.1 billion, with a median of $30.2 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Non-Current Debt slipped 18.23% in 2022, then rose 7.18% in 2026.
• Over 5 years, Non-Current Debt stood at $35.6 billion in 2022, then decreased by 14.24% to $30.6 billion in 2023, then retreated by 1.17% to $30.2 billion in 2024, then slipped by 13.93% to $26.0 billion in 2025, then climbed by 7.18% to $27.9 billion in 2026.
• The last three Non-Current Debt figures came in at $27.9 billion (Q1 2026), $26.0 billion (Q1 2025), and $30.2 billion (Q1 2024), per Business Quant data.